AI Article Synopsis

  • The study focuses on 11 patients diagnosed with thrombotic thrombocytopenic purpura (TTP) at a Brooklyn hospital from 2014 to 2020, highlighting patient demographics and treatment outcomes.
  • A significant portion of these patients were young, black, and female, with a notable prevalence of obesity and substance abuse among them.
  • Results indicated that drug abuse and obesity were linked to higher rates of acute kidney injury (AKI) and TTP exacerbations, suggesting the need for more research on these associations.

Article Abstract

This study aims to identify the baseline patient characteristics, clinical presentation, and response to treatment of 11 patients who were diagnosed with thrombotic thrombocytopenic purpura (TTP) between 2014 and 2020 at Brookdale University Hospital Medical Center, Brooklyn, NY. Laboratory and clinical parameters were recorded for 29 patients who received plasmapheresis in this time period. Of 29 patients, 11 had confirmed TTP and one was diagnosed with hereditary TTP. Young, black, and female patients made up the majority of our patient population. A high prevalence of obesity and drug abuse were seen among our patients. Five out of 11 were obese and four of them were morbidly obese; six out of 11 patients were positive for the drug screen including cannabinoids (3), opiates (2), benzodiazepines (1), PCP (1), and methadone (1). Four patients with a positive drug screen had acute kidney injury (AKI), and plasmapheresis helped them enhance their kidney function. We observed a high incidence of AKI and high TTP exacerbation rates in patients who were drug abusers and those who were morbidly obese. There is a paucity of data on the relationship of TTP with obesityor drug abuse and this needs further study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144271PMC
http://dx.doi.org/10.7759/cureus.14656DOI Listing

Publication Analysis

Top Keywords

drug abuse
12
patients
9
high incidence
8
thrombotic thrombocytopenic
8
thrombocytopenic purpura
8
obesity drug
8
abuse study
8
morbidly obese
8
patients positive
8
positive drug
8

Similar Publications

Background: Psychiatric disorders are a substantial public health concern, and childhood adversity a well-known risk factor for it. Investigating gender differences in vulnerability and resilience processes following out-of-home care (OHC) as proxy for childhood adversity can help map opportunities for the prevention of psychiatric disorders.

Methods: We followed a large birth cohort for psychiatric disorders (anxiety, depression, and self-harm, and substance misuse) between age 25-62 years, comparing individuals with and without OHC experience.

View Article and Find Full Text PDF

Importance: Cannabis use has increased globally, but its effects on brain function are not fully known, highlighting the need to better determine recent and long-term brain activation outcomes of cannabis use.

Objective: To examine the association of lifetime history of heavy cannabis use and recent cannabis use with brain activation across a range of brain functions in a large sample of young adults in the US.

Design, Setting, And Participants: This cross-sectional study used data (2017 release) from the Human Connectome Project (collected between August 2012 and 2015).

View Article and Find Full Text PDF

Effectiveness of a Dentist-based Anti-Smoking Intervention Among Malaysian Adolescents: A Randomized Controlled Field Trial.

Asian Pac J Cancer Prev

January 2025

Department of Community Oral Health and Clinical Prevention, Faculty of Dentistry, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.

Background:  The KOTAK program is a national public health initiative in Malaysian primary and secondary schools aimed at reducing youth smoking through school dental services. This study evaluated its effectiveness in Seremban, Negeri Sembilan, Malaysia.

Objectives: 1) To determine the percentage of schoolchildren who quit smoking through the KOTAK program; 2) To identify factors associated with quitting smoking in the program.

View Article and Find Full Text PDF

Background: Larsucosterol is a DNA methyltransferase inhibitor in development for alcohol-associated hepatitis (AH), a disease for which there is no approved therapy.

Methods: In this phase 2b trial, patients with severe AH were randomly assigned 1:1:1 to receive 30 mg or 90 mg of larsucosterol or placebo; a second dose was administered after 72 hours if the patient remained hospitalized. All patients received supportive care as determined by investigators.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!